RT Journal Article
SR Electronic
T1 Emergency Response for Evaluating SARS-CoV-2 Immune Status, Seroprevalence and Convalescent Plasma in Argentina
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.21.20216960
DO 10.1101/2020.10.21.20216960
A1 Ojeda, Diego S.
A1 Lopez Ledesma, María Mora Gonzalez
A1 Pallares, Horacio
A1 Costa Navarro, Guadalupe S.
A1 Sanchez, Lautaro
A1 Perazzi, Beatriz
A1 Villordo, Sergio M.
A1 Alvarez, Diego E.
A1 BioBanco Working Group
A1 Echavarria, Marcela
A1 Oguntuyo, Kasopefoluwa Y.
A1 Stevens, Christian S.
A1 Lee, Benhur
A1 Carradori, Jorge
A1 Caramelo, Julio J.
A1 Yanovsky, Marcelo J.
A1 Gamarnik, Andrea V.
YR 2020
UL http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216960.abstract
AB We report the emergency development and application of a robust serologic test to evaluate acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays, COVIDAR IgG and IgM, which were produced and provided for free to health authorities, private and public health institutions and nursing homes, use a combination of a trimer stabilized spike protein and the receptor binding domain (RBD) in a single enzyme-linked immunosorbent assay (ELISA) plate. Over half million tests have already been distributed to detect and quantify antibodies for multiple purposes, including assessment of immune responses in hospitalized patients and large seroprevalence studies in neighborhoods, slums and health care workers, which resulted in a powerful tool for asymptomatic detection and policy making in the country. Analysis of antibody levels and longitudinal studies of symptomatic and asymptomatic SARS-CoV-2 infections in over one thousand patient samples provided insightful information about IgM and IgG seroconversion time and kinetics, and IgM waning profiles. At least 35% of patients showed seroconversion within 7 days, and 95% within 45 days of symptoms onset, with simultaneous or close sequential IgM and IgG detection. Longitudinal studies of asymptomatic cases showed a wide range of antibody responses with median levels below those observed in symptomatic patients. Regarding convalescent plasma applications, a protocol was standardized for the assessment of end point IgG antibody titers with COVIDAR with more than 500 plasma donors. The protocol showed a positive correlation with neutralizing antibody titers, and was used to assess antibody titers for clinical trials and therapies across the country. Here, we demonstrate the importance of providing a robust and specific serologic assay for generating new information about antibody kinetics in infected individuals and mitigation policies to cope with pandemic needs.AUTHOR SUMMARY The development of robust and specific serologic assays to detect antibodies to SARS-CoV-2 is essential to understand the pandemic evolution and to stablish mitigation strategies. Here, we report the emergency development, production and application of a versatile ELISA test for detecting antibodies against the whole spike protein and its receptor binding domain. Over half million tests have been freely distributed in public and private health institutions of Argentina for evaluating immune responses, convalescent plasma programs and for large seroprevalence studies in neighborhoods and health care workers. We are still learning how and when to use serologic testing in different epidemiological settings. This program allowed us to produce large amount of high quality data on antibody levels in symptomatic and asymptomatic SARS-CoV-2 infections and generate relevant information about IgM and IgG seroconversion time and kinetics. We also present standardized protocols for antibody quantification as guidance for convalescent donor plasma selection in hospitals throughout the country for compassionate use and clinical trials. Here, we provide a framework for generating widely available tools, protocols and information of antibody responses for pandemic management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe COVIDAR project was funded by the CONICET through the Fondo para la Convergencia Estructural del Mercosur (FOCEM) and Agencia Argentina de Promocion Cientifica y Tecnologica PICT2017-1717 Annex COVID-19 to AVG. Founds were also provided by Fundacion Williams and Asociacion Civil SAND for COVIDAR and Serokit production and distribution.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bioethics Committee of Fundacion Instituto Leloir (HHS IRB # 00007572) (CBFIL Protocol #35)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data in the manuscript is available